Raymond James Financial Inc. Takes $651,000 Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Raymond James Financial Inc. acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 34,633 shares of the biotechnology company's stock, valued at approximately $651,000.

Other large investors have also bought and sold shares of the company. Xponance Inc. lifted its position in shares of Arrowhead Pharmaceuticals by 4.5% during the 4th quarter. Xponance Inc. now owns 17,400 shares of the biotechnology company's stock valued at $327,000 after buying an additional 744 shares during the last quarter. ADAR1 Capital Management LLC lifted its holdings in Arrowhead Pharmaceuticals by 10.2% during the 4th quarter. ADAR1 Capital Management LLC now owns 12,900 shares of the biotechnology company's stock worth $243,000 after purchasing an additional 1,195 shares in the last quarter. Van ECK Associates Corp lifted its holdings in Arrowhead Pharmaceuticals by 72.3% during the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 1,250 shares in the last quarter. KBC Group NV lifted its holdings in Arrowhead Pharmaceuticals by 45.9% during the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company's stock worth $98,000 after purchasing an additional 1,644 shares in the last quarter. Finally, Swiss National Bank lifted its holdings in Arrowhead Pharmaceuticals by 0.8% during the 4th quarter. Swiss National Bank now owns 220,000 shares of the biotechnology company's stock worth $4,136,000 after purchasing an additional 1,700 shares in the last quarter. 62.61% of the stock is owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Trading Up 6.8%

Arrowhead Pharmaceuticals stock traded up $0.88 during trading hours on Monday, reaching $13.91. The company had a trading volume of 934,051 shares, compared to its average volume of 1,457,625. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09. The company has a 50-day moving average price of $13.44 and a 200 day moving average price of $17.95. The firm has a market cap of $1.91 billion, a price-to-earnings ratio of -2.70 and a beta of 0.89. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $9.57 and a 12-month high of $30.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.97). Equities analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Christopher Richard Anzalone sold 133,333 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $17.02, for a total transaction of $2,269,327.66. Following the sale, the chief executive officer now directly owns 3,773,802 shares in the company, valued at $64,230,110.04. The trade was a 3.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold 275,880 shares of company stock valued at $4,034,037 in the last ninety days. Company insiders own 4.30% of the company's stock.

Analyst Ratings Changes

A number of analysts recently issued reports on ARWR shares. Chardan Capital reissued a "buy" rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. Royal Bank of Canada reissued an "outperform" rating and set a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. B. Riley reaffirmed a "buy" rating and issued a $38.00 price target (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the stock. According to MarketBeat, Arrowhead Pharmaceuticals presently has an average rating of "Hold" and a consensus price target of $41.44.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.